Add-on Studies / Sequential Design [Design Issues]

posted by joyjac – Philippines, 2006-07-19 07:10 (6284 d 09:00 ago) – Posting: # 179
Views: 10,865

I have some questions regarding add-on studies /sequential design.
  1. Are these acceptable in bioequivalence studies if specified a priori in the protocol? Would you know if US FDA, EMEA, Canada, ASEAN accept such design?
  2. When an add-on study is conducted (and combined with the original study), what would be the statistical method of analysis?
  3. Can we still apply the 90% Confidence Interval criteria for bioequivalence or would it have to be more restrictive i.e. 95% CI?
  4. Could the first study be discarded if the second study passed the 90% CI BE criteria on its own?
  5. More importantly, what are its pros and cons with regards to consumer protection or risk.
Thank you so much for the knowledge sharing.

Complete thread:

UA Flag
 Admin contact
22,764 posts in 4,776 threads, 1,628 registered users;
14 visitors (0 registered, 14 guests [including 7 identified bots]).
Forum time: 16:10 CEST (Europe/Vienna)

The object of statistics is information.
The objective of statistics is the understanding of information
contained in data.    Irwin and Marylees Miller

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz